Contribution of three CYP3A isoforms to metabolism of R- and S-warfarin.
Drew R Jones, So-Young Kim, Gunnar Boysen, Chul-Ho Yun, Grover P Miller
文献索引:Drug Metab. Lett. 4(4) , 213-9, (2010)
全文:HTML全文
摘要
Effective coumadin (R/S-warfarin) therapy is complicated by inter-individual variability in metabolism. Recent studies have demonstrated that CYP3A isoforms likely contribute to patient responses and clinical outcomes. Despite a significant focus on CYP3A4, little is known about CYP3A5 and CYP3A7 metabolism of warfarin. Based on our studies, recombinant CYP3A4, CYP3A5 and CYP3A7 metabolized R- and S-warfarin to 10- and 4'-hydroxywarfarin with efficiencies that depended on the individual enzymes. For R-warfarin, CYP3A4, CYP3A7, and CYP3A5 demonstrated decreasing preference for 10-hydroxylation over 4'-hydroxylation. By contrast, there was no regioselectivity toward S-warfarin. While all enzymes preferentially metabolized R-warfarin, CYP3A4 was the most efficient at metabolizing all reactions. Individuals, namely African-Americans and children, with higher relative levels of CYP3A5 and/or CYP3A7, respectively, compared to CYP3A4 may metabolize warfarin less efficiently and thus may require lower doses and be at risk for adverse drug-drug interactions related to the contributions of the respective enzymes.
相关化合物
相关文献:
2010-05-17
[Chem. Res. Toxicol. 23(5) , 939-45, (2010)]
2012-09-01
[Drug Metab. Lett. 6(3) , 157-64, (2012)]
2001-06-01
[Drug Metab. Dispos. 29(6) , 877-86, (2001)]
1989-03-01
[J. Pharm. Sci. 78(3) , 183-9, (1989)]